These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 21986113)
1. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting. Agarwal A; Agrawal H; Tiwari S; Jain S; Agrawal GP Int J Pharm; 2011 Dec; 421(1):189-201. PubMed ID: 21986113 [TBL] [Abstract][Full Text] [Related]
2. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859 [TBL] [Abstract][Full Text] [Related]
3. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. Lu W; Wan J; She Z; Jiang X J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471 [TBL] [Abstract][Full Text] [Related]
4. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles. Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113 [TBL] [Abstract][Full Text] [Related]
5. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Lu W; Tan YZ; Hu KL; Jiang XG Int J Pharm; 2005 May; 295(1-2):247-60. PubMed ID: 15848009 [TBL] [Abstract][Full Text] [Related]
6. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167 [TBL] [Abstract][Full Text] [Related]
7. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308 [TBL] [Abstract][Full Text] [Related]
9. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Pandey V; Gajbhiye KR; Soni V Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582 [TBL] [Abstract][Full Text] [Related]
10. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939 [TBL] [Abstract][Full Text] [Related]
11. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Mussi SV; Silva RC; Oliveira MC; Lucci CM; Azevedo RB; Ferreira LA Eur J Pharm Sci; 2013 Jan; 48(1-2):282-90. PubMed ID: 23178339 [TBL] [Abstract][Full Text] [Related]
12. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677 [TBL] [Abstract][Full Text] [Related]
13. Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes. Pang Z; Gao H; Chen J; Shen S; Zhang B; Ren J; Guo L; Qian Y; Jiang X; Mei H Int J Nanomedicine; 2012; 7():3421-32. PubMed ID: 22848168 [TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin. Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734 [TBL] [Abstract][Full Text] [Related]
16. Vascular targeting of doxorubicin using cationic liposomes. Wu J; Lee A; Lu Y; Lee RJ Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230 [TBL] [Abstract][Full Text] [Related]
17. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Benival DM; Devarajan PV Int J Pharm; 2012 Feb; 423(2):554-61. PubMed ID: 22155412 [TBL] [Abstract][Full Text] [Related]
18. An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery. Li S; Su Z; Sun M; Xiao Y; Cao F; Huang A; Li H; Ping Q; Zhang C Int J Pharm; 2012 Oct; 436(1-2):248-57. PubMed ID: 22732672 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
20. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice]. Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]